Novavax COVID-19 vaccine produces antibodies in small study
The Maryland-based biotechnology company said its vaccine candidate, NVX-CoV2373, produced higher levels of antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients, raising hopes for its eventual success.
The addition of its Matrix-M adjuvant, a substance designed to boost the body's immune response, enhanced the effect of the vaccine in the study, the company said.
The Novavax vaccine is among the first of a handful of programs singled out for U.S. funding under Operation Warp Speed, the White House program to accelerate access to vaccines and treatments that can fight the virus.
